Xultophy

11/01/2018 - "Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic."
01/01/2018 - "The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes."
11/01/2017 - "Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes."
01/01/2022 - "Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients. "
11/01/2018 - "Xultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetes patients since 2014. "

03/01/2017 - "Insulin degludec/liraglutide (Xultophy 100/3.6) for type-2 diabetes; rucaparib (Rubraca) for the treatment of deleterious BRCA mutation-associated ovarian cancer; and nusinersen (Spinraza) for the treatment of spinal muscular atrophy."

11/01/2018 - "Xultophy was well-tolerated, however, abdominal cramps and nausea limited use in three patients. "

03/01/2017 - "Insulin degludec/liraglutide (Xultophy 100/3.6) for type-2 diabetes; rucaparib (Rubraca) for the treatment of deleterious BRCA mutation-associated ovarian cancer; and nusinersen (Spinraza) for the treatment of spinal muscular atrophy."

11/01/2018 - "Xultophy was well-tolerated, however, abdominal cramps and nausea limited use in three patients. "